Lymphocyte Transplantation CD3
Also known as: CD3
Use
The Lymphocyte Transplantation CD3 test monitors the response to CD3 immunosuppressive therapy. It is utilized to verify the effectiveness of immunosuppressive treatment, specifically OKT3, by documenting CD3 antigen removal. This test is crucial for transplant patients to ensure immunosuppressive therapy is functioning as intended, thus helping manage and adjust treatment regimens to prevent transplant rejection and optimize patient outcomes.
Special Instructions
Specimens must be collected before administering immunosuppressive medications. The test is specifically designed for transplant patients only. For immunocompromised patients, an alternative test, the Lymphocyte Subset Panel 4 - T-Cell subsets Percent & Absolute (0095950), should be ordered.
Limitations
This test has not been cleared or approved by the US Food and Drug Administration. It is developed and its performance characteristics are determined by ARUP Laboratories in a CLIA certified laboratory for clinical purposes. Specimens that are clotted or hemolyzed are unacceptable. Additionally, specimens must be analyzed within 72 hours of collection and cannot be frozen for stability reasons.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 8124-0
- 8122-4
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL
Minimum Volume
0.5 mL
Container
Green (Sodium or Lithium Heparin), Lavender (EDTA), or Pink (K2EDTA)
Patient Preparation
Draw specimen before administering immunosuppressive medications.
Storage Instructions
Room temperature. Also acceptable: Refrigerated.
Causes for Rejection
Clotted or hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 72 hours |
| Frozen | Unacceptable |